Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | CTSK | P43235 | 11/20 | 0.40 |
| ▸ | CTSS | P25774 | 7/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 1/20 | 0.37 |
| ▸ | CA7 | P43166 | 1/20 | 0.37 |
| ▸ | CTSL | P07711 | 1/20 | 0.36 |
| ▸ | CTSB | P07858 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.35 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15456301 | 1.00 | SMN1; SMN2 (0.41) | SMN1; SMN2CTSKCTSSCA1CA2 | |
| SCHEMBL28511486 | 0.82 | CYP2D6 (0.47) | SMN1; SMN2CTSKCTSSCA1CA2 | |
| SCHEMBL9754187 | 0.82 | CTSK (0.52) | CTSKCTSSCA1CA2CA7 | |
| SCHEMBL28216119 | 0.82 | CTSK (0.42) | CTSKCTSSCA1CA2CA7 | |
| SCHEMBL18428130 | 0.82 | CTSK (0.42) | CTSKCTSSCA1CA2CA7 | |
| SCHEMBL28511485 | 0.82 | CYP2D6 (0.47) | SMN1; SMN2CTSKCTSSCA1CA2 | |
| SCHEMBL20072905 | 0.81 | SMN1; SMN2 (0.43) | SMN1; SMN2CTSKCTSSCA1CA2 | |
| SCHEMBL2728681 | 0.79 | CTSK (0.47) | SMN1; SMN2CTSKCTSSCA1CA2 | |
| SCHEMBL212773 | 0.79 | CTSK (0.47) | SMN1; SMN2CTSKCTSSCA1CA2 | |
| SCHEMBL16289367 | 0.79 | SMN1; SMN2 (0.49) | SMN1; SMN2CTSKCTSSCA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220081423-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2022-03-17 | — | — | US | disclosed |
| US-20180105504-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2018-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220081423-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | TRPV1, HCN4, TRPA1 | SMN1; SMN2 417/4885CTSK 2607/4885CTSS 2205/4885 |
| US-20180105504-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | NPY5R, REN, F12 | SMN1; SMN2 1229/4885CTSK 2350/4885CTSS 1981/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.